{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:24:50Z","timestamp":1767983090937,"version":"3.49.0"},"reference-count":19,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"published-print":{"date-parts":[[2016]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; Pemetrexed is an antifolate chemotherapeutic agent approved for use in non-small cell lung cancer (NSCLC). The mammalian target of rapamycin (mTOR) pathway is implicated in lung cancer development and inhibited by temsirolimus. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; We performed a phase I study evaluating the combination of pemetrexed and temsirolimus in advanced non-squamous NSCLC. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; Eight patients were enrolled in this study. The dose-limiting toxicities included grade 4 thrombocytopenia, grade 3 leukopenia and grade 3 neutropenia. The maximum tolerated dose was determined to be pemetrexed 375 mg\/m&lt;sup&gt;2&lt;\/sup&gt; intravenously on day 1 and temsirolimus 25 mg intravenously on days 1, 8 and 15. No objective responses were noted and 3 patients had stable disease as the best response. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; The combination of pemetrexed and temsirolimus is feasible and well tolerated. This combination may be further evaluated in patients with mTOR pathway activation, particularly in those with &lt;i&gt;TSC1&lt;\/i&gt; or &lt;i&gt;STK11&lt;\/i&gt; mutations.<\/jats:p>","DOI":"10.1159\/000442147","type":"journal-article","created":{"date-parts":[[2016,1,18]],"date-time":"2016-01-18T22:01:21Z","timestamp":1453154481000},"page":"144-147","source":"Crossref","is-referenced-by-count":18,"title":["A Phase I Trial of Temsirolimus and Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer"],"prefix":"10.1159","volume":"61","author":[{"given":"Saiama N.","family":"Waqar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Q.","family":"Baggstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Morgensztern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caron","family":"Rigden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramaswamy","family":"Govindan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2016,1,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21254"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.4859"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181c5920c"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011954"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70393-X"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214886"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159\/000371735"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.163"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159\/000343048"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)00117-3"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066838"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.185"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.185"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31824de0d6"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1760"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-4979"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182307ede"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1126\/science.1226344"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2011.98"}],"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/442147","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/442147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:06:22Z","timestamp":1745431582000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000442147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":19,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,4,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000442147","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"value":"0009-3157","type":"print"},{"value":"1421-9794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}